# High-affinity nitrogen-doped graphene quantum dots for selective in vivo and ex vivo detection of amyloid-β plaques in an Alzheimer's disease rat model

## TL;DR

Researchers developed nitrogen-doped graphene quantum dots that can detect amyloid-β plaques in Alzheimer's disease rat models with high accuracy and selectivity.

## Contribution

This is the first demonstration of nitrogen-doped graphene quantum dots for in vivo and ex vivo detection of Aβ aggregates in an Alzheimer's disease model.

## Key findings

- Nitrogen-doped graphene quantum dots (N-GQDs) showed high photostability, biocompatibility, and quantum yield for Aβ detection.
- N-GQDs selectively bound to Aβ aggregates with strong interactions confirmed by molecular docking analysis.
- In vivo imaging in AD rat models showed a 2-fold increase in fluorescent intensity compared to control rats.

## Abstract

Early and precise detection of the amyloid-β (Aβ) aggregates is a critical factor in understanding Alzheimer's disease (AD) pathology. Current fluorescent probes for detecting Aβ plaques suffer from poor photostability, low selectivity, and ineffective blood–brain barrier (BBB) permeability, hindering in vivo imaging efficacy. Herein, we develop the first demonstration of nitrogen-doped graphene quantum dots (N-GQDs) as multifunctional fluorescent probes enabling sensitive, selective, and real-time in vivo and ex vivo imaging of Aβ aggregates in an AD rat model that overcomes previous limitations. Unlike conventional organic dyes, our N-GQDs combine high photostability with enhanced biocompatibility (cytotoxicity <10% at 250 µg mL−1) and high quantum yield (57.3%). Their nanoscale size (7.4 nm) facilitates efficient BBB penetration and rapid clearance, addressing a major challenge in existing Aβ imaging agents. Nitrogen doping increases the affinity and selective binding interactions of GQDs with Aβ aggregates by introducing active sites and modifying their electronic structure. N-GQDs showed a fluorescence enhancement specifically upon binding to Aβ25–35 aggregates, providing sensitive detection at concentrations as low as 1.6 µM. Molecular docking analysis confirmed a strong and stable interaction (−57.4 kcal mol−1) between N-GQDs and Aβ25–35 aggregates, supporting the observed selectivity. Following intravenous injection of the N-GQDs, the fluorescent intensity in the brain of the AD model rats showed a ∼2-fold increase compared to that of control rats, consistent with ex vivo biodistribution studies. These findings establish N-GQDs as the first graphene-based platform for non-invasive, selective in vivo detection of Aβ plaques, offering them as a diagnostic agent for AD pathology.

Early and precise detection of the amyloid-β (Aβ) aggregates is a critical factor in understanding Alzheimer's disease (AD) pathology.